Brii Biosciences Limited (7SS) - Total Assets
Based on the latest financial reports, Brii Biosciences Limited (7SS) holds total assets worth €2.36 Billion EUR (≈ $2.76 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Brii Biosciences Limited - Total Assets Trend (2020–2025)
This chart illustrates how Brii Biosciences Limited's total assets have evolved over time, based on quarterly financial data. Also see 7SS company net worth for the company's overall valuation and market capitalisation.
Brii Biosciences Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
Brii Biosciences Limited's total assets of €2.36 Billion consist of 83.2% current assets and 16.8% non-current assets. Review 7SS liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 25.7% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €298.02 Million | 12.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Brii Biosciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 7SS stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Brii Biosciences Limited's current assets represent 83.2% of total assets in 2025, a decrease from 86.2% in 2020.
- Cash Position: Cash and equivalents constituted 25.7% of total assets in 2025, down from 81.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 12.6% of total assets.
Brii Biosciences Limited Competitors by Total Assets
Key competitors of Brii Biosciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Brii Biosciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 60.73 | 31.18 | 13.43 |
| Quick Ratio | 60.73 | 31.18 | 13.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.93 Billion | €2.34 Billion | €2.85 Billion |
Brii Biosciences Limited - Advanced Valuation Insights
This section examines the relationship between Brii Biosciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.33 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -12.8% |
| Total Assets | €2.36 Billion |
| Market Capitalization | $72.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Brii Biosciences Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Brii Biosciences Limited's assets decreased by 12.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Brii Biosciences Limited (2020–2025)
The table below shows the annual total assets of Brii Biosciences Limited from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.36 Billion ≈ $2.76 Billion |
-12.82% |
| 2024-12-31 | €2.71 Billion ≈ $3.16 Billion |
-15.37% |
| 2023-12-31 | €3.20 Billion ≈ $3.74 Billion |
-5.71% |
| 2022-12-31 | €3.39 Billion ≈ $3.97 Billion |
-6.09% |
| 2021-12-31 | €3.61 Billion ≈ $4.22 Billion |
+184.85% |
| 2020-12-31 | €1.27 Billion ≈ $1.48 Billion |
-- |
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neut… Read more